Category Archives: Innovation

Indian Civil Society letter on TB Declaration negotiations -UN High Level Meeting

To, Mr. Narendra Modi, Prime Minister of India Mr. J. P. Nadda, Health Minister Ms. Sushma Swaraj, Foreign Minister Mr. Suresh Prabhu, Commerce Minister Date: 31st July 2018 Sub: Asking India to support TRIPS flexibilities in UN High Level Meeting on TB … Continue reading

Posted in Access to Medecines, Delinkage, R&D, TRIPS, TRIPS flexibilities, Tuberculosis (TB), Uncategorized | Leave a comment

The switch from patents to state-dependent prizes for technological innovation

by Hwan C. Lin, Journal of Macroeconomics Volume 50, December 2016, Pages 193-223 Highlights •Examine the intertemporal bounty (IB) system as an alternative to patents. •The IB system rewards innovation with a bounty claim to state-dependent prizes (called “intertemporal bounties”) over time. … Continue reading

Posted in Innovation, Patent, Patent examination system, Uncategorized | Leave a comment

Draft TB declaration: US, EU push against funding, delinkage pledges

Source: POLITICO PRO| June 12, 2018 The EU and U.S. are resisting concrete commitments on new funding for tuberculosis ahead of a high-level U.N. meeting about fighting the world’s top infectious killer. The two regions are also pushing to eliminate language … Continue reading

Posted in Delinkage, Tuberculosis (TB) | Leave a comment

Pharmaceutical corporations need to stop free-riding on publicly-funded research

by Jason Cone, The Hill The White House Council of Economic Advisers recently announced a strategy to curb high drug prices: force “free riding” countries abroad to pay more and watch the prices go down in America. That’s not how … Continue reading

Posted in Public funded research, Public research, R&D, Uncategorized | Leave a comment

Letter to US Secretary of Health and Human Services by US-based groups

25th May 2018 New Delhi On Friday, 18th May 2018  27 US-based groups sent a letter to the US Secretary of Health and Human Services calling for increased transparency in the biomedical innovation system. The letter can be read here. … Continue reading

Posted in Access to Medecines, Drug prices, Innovation, US debate on spiraling drug prices | Leave a comment

Breaking news for access to biological medicines – Brazilian court nixes biological drug eculizumab patent, says more could follow

Source: BioCentury | April 21, 2018 A Brazilian court unanimously ruled Friday to remove patent protection for Soliris eculizumab from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), opening the door for production of biosimilar versions in the country. In a statement, Brazil’s Attorney General Office said … Continue reading

Posted in Access to Medicins, Brazil Patent Reform, Open access, Patent, Regulation | Leave a comment

Draft Pharmaceutical Policy, 2017

Source: All India Drug Action Network (AIDAN) The Department of Pharmaceuticals has circulated a Draft Pharmaceutical Policy, 2017 which can be accessed here. The draft policy identifies the following key objectives: a. Making essential drugs accessible at affordable prices to the … Continue reading

Posted in API, Biologics/Biosimilars, Evergreening, Innovation, IPR, Patent, R&D, Uncategorized | Leave a comment